To our knowledge, compared to recently published systematic review articles on this topic [20,36,40,41], this is the largest and most updated systematic review and meta-analysis of RCTs that used different GLP-1 RAs (also including two newer long-acting injectable GLP-1 RAs, such as dulaglutide and semaglutide), for the treatment of NAFLD or NASH, irrespective of T2DM status. Here, GLP1R is linked to metabolic dysfunction-associated steatohepatitis.